Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Gils Roex; Tom Feys; Yves Beguin; Tessa Kerre; Xavier Poiré; Philippe Lewalle; Peter Vandenberghe; Dominique Bron; Sébastien Anguille

doi:10.3390/pharmaceutics12020194

Pharmaceutics (Feb 2020)

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Gils Roex,
Tom Feys,
Yves Beguin,
Tessa Kerre,
Xavier Poiré,
Philippe Lewalle,
Peter Vandenberghe,
Dominique Bron,
Sébastien Anguille

Affiliations

Gils Roex: Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium
Tom Feys: Ariez International BV, 9000 Ghent, Belgium
Yves Beguin: Department of Hematology, University of Liège, 4000 Liège, Belgium
Tessa Kerre: Department of Hematology, University Hospital Ghent, 9000 Ghent, Belgium
Xavier Poiré: Faculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium
Philippe Lewalle: Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium
Peter Vandenberghe: Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
Dominique Bron: Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium
Sébastien Anguille: Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium

DOI: https://doi.org/10.3390/pharmaceutics12020194
Journal volume & issue: Vol. 12, no. 2
p. 194

Abstract

Read online

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.

Published in Pharmaceutics

ISSN: 1999-4923 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Pharmacy and materia medica
Website: http://www.mdpi.com/journal/pharmaceutics/

About the journal

Abstract

Keywords